Sagimet Biosciences (SGMT) Liabilities and Shareholders Equity (2022 - 2026)

Sagimet Biosciences' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $107.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 26.28% year-over-year to $107.8 million; the TTM figure through Mar 2026 stood at $490.0 million (down 26.88% YoY), while the FY2025 annual figure was $116.5 million, down 27.32% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $107.8 million, down from $116.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $194.5 million in Q1 2024, with the low at $21.5 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $128.4 million (2025), against an average of $123.8 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 779.24% in 2024, then fell 27.32% in 2025.
• Sagimet Biosciences' Liabilities and Shareholders Equity stood at $33.0 million in 2022, then soared by 192.81% to $96.7 million in 2023, then surged by 65.7% to $160.3 million in 2024, then dropped by 27.32% to $116.5 million in 2025, then fell by 7.49% to $107.8 million in 2026.
• Business Quant data shows SGMT's Liabilities and Shareholders Equity at $107.8 million in Q1 2026, $116.5 million in Q4 2025, and $128.4 million in Q3 2025.